Gilead and ‘Good News’ Make A Rare, Joint Appearance at HIV Conference

With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise. Bictegravir, the company’s next-generation integrase inhibitor, suppressed the HIV virus in newly diagnosed patients better than dolutegravir, a similar, rival drug from GlaxoSmithKline , according to results from a mid-stage clinical trial announced Monday night.

Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus

GlaxoSmithKline reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug and the recent pace of organic growth for new products sales. GlaxoSmithKline Plc reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug in the U.S. and the recent pace of organic growth for new products sales.